Market Overview

Abreos Biosciences Launches Laboratory Developed Test for Precision Dose Monitoring of Natalizumab (Tysabri)

Share:

Abreos Biosciences Launches Laboratory Developed Test for Precision Dose Monitoring of Natalizumab (Tysabri)

Novel assay addresses substantial unmet need for physicians to more effectively monitor biologic drug levels in patients.

PR Newswire

SAN DIEGO, Aug. 22, 2018 /PRNewswire-PRWeb/ -- Abreos Biosciences, a San Diego-based biotech company and leader in the precision dosing of biological therapeutics, is pleased to announce the launch of its first commercial product, moNATor, a laboratory developed test (LDT) used to aid physicians in the monitoring of Tysabri (natalizumab) levels in patients with multiple sclerosis.

In light of the recent Biogen announcements (TOUCH database) showing a significant reduction in progressive multifocal leukoencephalopathy (PML) risk for patients on extended interval dosing (EID), moNATor provides an individual Tysabri concentration level to help guide physicians in decision making regarding optimal dosing intervals.

"Biologics are among the most powerful therapeutics available for many serious diseases, yet many patients are under or over-dosed due to the lack of simple monitoring tests that can tell how much drug a patient has in their blood. We are hoping to make personalized, precision dosing a reality for these patients," said Bradley Messmer, Ph.D., CEO and founder of Abreos.

The patent protected Abreos  Veritope™ technology platform  allows for the selective monitoring of therapeutic antibody drugs, whether brand name or biosimilars. By monitoring the levels of these therapies, clinicians can optimize therapeutic dose and timing to help achieve ideal response and safety to these expensive therapies.

moNATor was pre-launched to a select group of thought-leading physicians and has already been successfully used with hundreds of patients. The initial cohort of influential users views moNATor as an important assay for neurological physicians specializing in treating patients with relapsing-remitting multiple sclerosis that are on Tysabri.

"The MS community is working to optimize drug safety in the therapeutics area, and I feel the recent data regarding Tysabri dosing interval extension and PML risk reduction is a major advance. The moNATor assay provides another tool to the clinician which may help to optimize patient care through precision Tysabri dosing." - John Foley, MD, founder Rocky Mountain MS Clinic

The moNATor test is now commercially available in the United States. For more information please visit http://www.abreos.com or contact info(at)abreosbio(dot)com.

 

SOURCE Abreos Biosciences

View Comments and Join the Discussion!